Clinical Efficacy of Doripenem in Treating Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: A Systematic Review and Meta-Analysis
Abstract
This meta-analysis investigated whether the clinical efficacy of doripenem is comparable to that of alternative antibiotics for treating hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). The PubMed, Web of Science, Cochrane Library, Ovid MEDLINE, and EBSCO databases were searched for literature published before October 20, 2021. Clinical studies comparing the efficacy of doripenem with that of other antibiotics in HAP/VAP treatment were included. Primary outcomes included all-cause mortality at 28 to 30 days, whereas the secondary outcome was the clinical cure rate. In total, 5 clinical studies were included in this meta-analysis. All-cause mortality did not differ significantly between doripenem and the comparators. For VAP alone, no statistical differences were observed between doripenem and the comparators. For Pseudomonas aeruginosa-related pneumonia, mortality did not differ between doripenem and the comparators. The clinical cure rates were 60.7% and 57.3% for doripenem and the comparators, respectively; a similar trend was observed in the subgroup analysis for VAP. For HAP/VAP due to P. aeruginosa, the clinical cure rates for doripenem and the comparators did not differ. Doripenem was comparable to other antibiotics in the treatment of HAP and VAP.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.